<DOC>
	<DOCNO>NCT01340625</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 0.4 mg/35 mcg Norethindrone Ethinyl Estradiol Chewable Tablets Teva Pharmaceuticals , USA 0.4 mg/35 mcg OvconÂ® 35 Fe Chewable Tablets manufacture Warner Chilcott Company , Inc. , follow single oral dose ( 2 * 0.4 mg/35 mcg chewable tablet ) healthy female adult volunteer administer fasting condition .</brief_summary>
	<brief_title>Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Norinyl</mesh_term>
	<mesh_term>Norethindrone acetate , ethinyl estradiol , ferrous fumarate drug combination</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<criteria>Volunteers inform nature study agree read , review , sign inform consent document prior Period I dose . Volunteers complete screen process within 28 day prior Period I dose . Volunteers healthy adult woman 1835 year age , inclusive , time dose . Volunteers body mass index ( BMI ) 1930 kg/m2 , inclusive , weight least 110 lb . Volunteers healthy document medical history , physical examination , vital sign assessment , 12lead electrocardiogram , clinical laboratory assessment , general observation . The physical examination also include gynecological exam . If subject complete acceptable Papanicolaou smear gynecological exam previous 12 month documentation acceptable result provide , deferred . Any abnormalities/deviations normal range might consider clinically relevant study physician investigator evaluate individual case , document study file , agree upon study physician investigator prior enrol volunteer study continue enrollment . Volunteers must practice acceptable nonhormonal birth control method judge investigator ( ) least 14 day prior Period I dose , throughout study , 14 day second period dose . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take oral contraceptive include estrogen progestin combine pill progestin pill patch within 28 day prior Period I dose , use injectable contraceptive within 6 month first period dose . Volunteers ever progestational hormone implant . Volunteers report presence history clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system psychiatric disease determine clinical investigator ( ) . Volunteers report presence history migraine severe headache . Volunteers systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 45 90 mmHg exclude study . Volunteers history thrombotic disorder ever cerebrovascular accident transient ischemic attack . Volunteers history breast cancer undiagnosed breast nodule , active malignancy undiagnosed vaginal bleeding . Volunteers condition may aggravate fluid retention ( determine principal investigator ) . Volunteers history jaundice previous use oral contraceptive kinds hormonal contraceptive . Volunteers whose clinical laboratory test value fall outside accepted reference range confirm reexamination deem clinically significant . Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Volunteers report history allergic response ( ) norethindrone/ethinyl estradiol progestin/estrogens relate drug . Volunteers report use systemic prescription medication 14 day prior Period I dose ( exception hormonal contraceptive ) . Volunteers history clinically significant allergy include drug allergy . Volunteers report clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers report history drug alcohol addiction abuse within past year . Volunteers demonstrate positive drug abuse screen study prior Period I dose administration . Volunteers currently use use tobacco product within 30 day prior Period I dose . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood 4 week complete study . Volunteers report donate plasma within 30 day prior Period I dose . All subject advise donate plasma 4 week complete study . Volunteers demonstrate positive pregnancy screen . Volunteers currently pregnant breastfeed . Volunteers use use within 3 month precede Period I dose vaginally administer estrogen progestincontaining product . Any volunteer engage unprotected sexual intercourse time interval start 14 day prior first period dose 14 day Period II dosing . Volunteers hysterectomy oophorectomy ( unilateral bilateral ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>